Find out how our team of experts at Virtus have helped to investigate the efficacy, safety and pharmacodynamics of a new inhaled immunomodulator.

Pulmotect wanted to generate a comprehensive dataset on the safety, pharmacodynamics and potential
efficacy of PUL-042 to inform future trial design in COPD subjects, which was a potential target indication.

Discover how Virtus designed, conducted and analysed a human challenge study.

• • 100% successful infection rate
  • Demonstrated safety in target population
  • Over 30,000 unique data points generated
  • New biomarkers identified suggesting a unique mechanism of action

Find out more here: Case Study